Jakarta – BRIN Public Relations. The facilitation scheme for the health innovation product testing (PPIK) launched by the National Research and Innovation Agency (BRIN) is expected to narrow the gap that occurs in research in the health sector. This was shared by the Head of BRIN, Laksana Tri Handoko in a Webinar on Research and Innovation Funding Facilitation, edition of Health Innovation Product Testing Facilitation, batch I, Tuesday (15/03).
According to Handoko, the gap occurs both from the side of researchers and the industry. From the side of researchers, there are still many who do not understand how to transform the results of a research in the health sector into a product that is ready to be commercialized.
On the other hand, the industry is still hesitant to get involved in the process of testing health innovation products considering the magnitude of the risks involved. “The industry is hesitant to make research products commercial, because they are not able and are not willing to bear the risk of failure that is quite large,” said Handoko.
For this reason, Handoko explained, BRIN is here to provide funding for health innovation product testing, and assume the possible risk of failure that may occur. With this facilitation scheme, it is hoped that many industries will be interested and willing to collaborate with researchers from both inside and outside BRIN to be involved in research and testing activities for health innovation products.
At the end of 2021, BRIN invited researchers from BRIN, the industry and universities to register as recipients of health product and innovation testing facilitation. This scheme continues throughout the year, and the topic is not only limited to health innovation products, but will also develop to other sectors such as agriculture, aerospace, nuclear technology, and so on.
Acting Deputy for Research and Innovation Facilitation, Agus Haryono, reported that in the first stage, BRIN received 30 proposals for the facilitation scheme for health innovation products testing. In the subsequent administrative selection, 28 proposals were declared passed the administrative selection.
In the next process, of the 28 proposals, 20 proposals were declared passed the substance selection. “To be able to pass the stage of substance selection, the products to be submitted for preclinical and clinical testing must be declared scientifically proven, which can be proven by scientific publications that support the product,” said Agus.
Publication is often an obstacle for the industry, because research activities in the industry are sometimes not documented in the form of scientific publications. As a solution, Agus offered that the industry can cooperate with researchers from BRIN who can help them publish the results of research activities in the industry.
“This publication is one of indicators that the results of a research have been examined by experts in their fields,” added Agus.
The requirements of proposal substance are viewed from its urgency or priority, the level of product readiness, and preferably those with industrial partners. If they have met the requirements in terms of urgency and product readiness, but do not have partners, BRIN through the Deputy for Research and Innovation Utilization will try to find them partners that will accompany the process of testing health innovation products.
“The next stage was presentation in front of the reviewers. 3 proposals passed to be able to receive funding facilitation for testing health innovation products,” he explained.
The three candidates who passed and received PPIK facilitation, Batch I in 2022 are, first, I Nyoman Honest from the Nanotechnology and Materials Research Organization – Advanced Materials Research Center, in collaboration with PT. Zenith Allmar for the development of Spine Implant Prototype which is one of products in the National Research Priority (PRN) activity.
Second, Erry Dwi Kurniawan from the Electronics & Informatics Research Organization – Telecommunication Research Center, in collaboration with PT. Tesena Inovindo for the development of CPAP-BiPAP Ventilators;
Third, Zullies Ikawati from Gadjah Mada University in collaboration with PT. Konimex, which will develop Phytopharmaca Drug Candidate for Cognitive Enhancer from Secang Wood Extract.
The three proposals for facilitation recipients have been submitted to the deputy for research and innovation utilization for the next stage, namely pre-clinical trials or clinical trials. Through this PPIK facilitation funding scheme, Agus hopes that many private parties are interested in being involved in research activities and commercializing research products, especially in the health sector, to the public.
“The hope is that the research results from researchers, which initially were on a laboratory scale, will become commercialized, by of course, collaborating with the industry that will produce and commercialize them to the public,” Agus hoped. (pur)